Regentis Biomaterials Ltd. (AMEX:RGNT) Financings

Regentis Biomaterials Ltd.

Financings

RaiseDate
Private placement of ordinary shares (or pre-funded warrants) with ordinary warrants
Announced: about US$6.5M · US$3.5 a share · Warrants at US$4.2 for 60 months · ThinkEquity
Dealers: ThinkEquity (lead)
Use of proceeds: GelrinC pivotal trial and FDA PMA preparation, Gelrin platform, manufacturing scale-up, European market entry, working capital
Jun 18, 2026
Public offering of ordinary shares
Closed: US$10M raised · US$8 a share · ThinkEquity
Dealers: ThinkEquity (lead)
Use of proceeds: Development activities including completing its pivotal trial and PMA submission prep for GelrinC, plus debt repayment and deferred compensation
Dec 5, 2025

Read by 6ix AI from the company's releases